Pacific Biosciences
PACB
151 hedge funds and large institutions have $375M invested in Pacific Biosciences in 2020 Q2 according to their latest regulatory filings, with 34 funds opening new positions, 47 increasing their positions, 38 reducing their positions, and 15 closing their positions.
127% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 15
116% more call options, than puts
Call options by funds: $1.18M | Put options by funds: $545K
24% more repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 38
14% more funds holding
Funds holding: 132 → 151 (+19)
6.37% less ownership
Funds ownership: 76.87% → 70.5% (-6.4%)
41% less capital inflows, than outflows
Capital inflows: $41.2M | Capital outflows: $69.7M
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ARK Investment Management
St. Petersburg,
Florida
|
+$13.7M |
| 2 |
Morgan Stanley
New York
|
+$3.94M |
| 3 |
Bellevue Group
Kuesnacht,
Switzerland
|
+$3.35M |
| 4 |
State Street
Boston,
Massachusetts
|
+$2.25M |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
+$2.14M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Weiss Multi-Strategy Advisers
New York
|
-$13.7M |
| 2 |
ArrowMark Colorado Holdings
Denver,
Colorado
|
-$8.62M |
| 3 |
Camber Capital Management
Boston,
Massachusetts
|
-$7.65M |
| 4 |
Goldman Sachs
New York
|
-$5.78M |
| 5 |
Kite Lake Capital Management (UK)
London,
United Kingdom
|
-$5.08M |
PACB Hedge Fund Activity: Q2 2020 in Review
151 of the 4,890 institutional investors tracked by Wall St. Rank reported a position in Pacific Biosciences (PACB) for Q2 2020, worth a combined $375M — up 4% from $361M a quarter earlier.
Buyers outnumbered sellers: 34 funds opened new PACB positions and 15 closed out — a net gain of 19 holders — while 47 added to existing stakes and 38 trimmed.
The largest buyer was ARK Investment Management, adding an estimated $13.7M. The largest seller was Weiss Multi-Strategy Advisers, cutting an estimated $13.7M.
- 151 institutional investors held Pacific Biosciences (PACB) as of Q2 2020, up from 132 in Q1 2020.
- Funds reported $375M of Pacific Biosciences stock for Q2 2020, up 4% quarter-over-quarter.
- 34 funds opened new Pacific Biosciences positions in Q2 2020 and 15 closed out, a net change of +19 holders.
- The largest Pacific Biosciences buyer in Q2 2020 was ARK Investment Management, an estimated $13.7M added.
- The largest Pacific Biosciences seller in Q2 2020 was Weiss Multi-Strategy Advisers, an estimated $13.7M sold.
Based on aggregated 13F filings for Q2 2020.